Skip to main content

Pancreatic Cancer Clinical Trials

Review the pancreatic cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 279

Pegcetacoplan in Combination with Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
AGEN2373 in Combination with GVAX or mKRASvax for the Treatment of Patients with Stage I or II Resectable Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Immunotherapy (EGFR FPBMC) for the Treatment of Locally Advanced, Metastatic, or Unresectable Pancreatic Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Erlotinib, Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Basal-Like Pancreatic Cancer, PANGEA Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Gemcitabine and Nab-Paclitaxel With or Without ONT01 for the Treatment of Unresectable/Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Bosentan with Nab-Paclitaxel and Gemcitabine for the Treatment of Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
9-ING-41 and Retifanlimab with FOLFIRINOX for the Treatment of Advanced Recurrent or Metastatic Pancreatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York